Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $28.0 million.

  • Ultragenyx Pharmaceutical's Other Operating Expenses rose 3315.73% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 3431.04%. This contributed to the annual value of $76.7 million for FY2024, which is 6971.84% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Other Operating Expenses of $28.0 million as of Q3 2025, which was up 3315.73% from $23.0 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Other Operating Expenses' 5-year high stood at $28.7 million during Q1 2025, with a 5-year trough of $3.1 million in Q2 2021.
  • Moreover, its 5-year median value for Other Operating Expenses was $11.0 million (2023), whereas its average is $12.9 million.
  • Data for Ultragenyx Pharmaceutical's Other Operating Expenses shows a peak YoY increase of 24810.16% (in 2021) and a maximum YoY decrease of 3597.88% (in 2021) over the last 5 years.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other Operating Expenses (Quarter) stood at $3.5 million in 2021, then skyrocketed by 51.58% to $5.3 million in 2022, then skyrocketed by 126.57% to $12.1 million in 2023, then surged by 40.19% to $16.9 million in 2024, then surged by 65.69% to $28.0 million in 2025.
  • Its last three reported values are $28.0 million in Q3 2025, $23.0 million for Q2 2025, and $28.7 million during Q1 2025.